Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

YBX1, Targeted By Microrna-382-5p, Promotes Laryngeal Squamous Cell Carcinoma Progression via Modulating RAS/MAPK Signaling

Author(s): Wen Zeng, Yiyun Pan, Hailong Chen, Xianhua Lei and Xiangmin Zhang*

Volume 19, Issue 2, 2024

Published on: 20 February, 2023

Page: [176 - 187] Pages: 12

DOI: 10.2174/1574892818666230207091720

Price: $65

Abstract

Background: Laryngeal squamous cell carcinoma (LSCC) is the most common cancer of head and neck cancer. Y-box binding protein-1 (YBX1) has tumor-promoting effects in some types of cancers. However, its role in LSCC remains unknown. This study set out to identify the role of YBX1 in LSCC.

Methods: Bioinformatics analysis of the Gene Expression Omnibus (GEO) database and our cohort data were used to explore the association of YBX1 expression with clinicopathological factors in LSCC. Then, cells with stably or transiently transfected with plasmid or siRNA were constructed to assess the effect of loss and gain of YBX1 on the biological phenotypes of LSCC cells in vitro. In addition, subcutaneous xenograft and orthotopic liver tumor mouse models were constructed for validation. The interrogated miRNA databases and subsequent luciferase reporter assays were used to confirm the miR-382-5p target of YBX1. At last, KEGG enrichment annotation from TGCA data was used for downstream analyses of miR-382-5p/YBX1 and verified by PCR and Western immunoblotting.

Results: The results showed that significant upregulation of YBX1 in LSCC tumors was correlated with advanced TNM stage and poor prognosis. Knockdown of YBX1 markedly impaired the proliferative, invasive, and migratory activity of Tu212 cells. We confirmed that miR-382-5p targets YBX1 to mediate LSCC progression both in vitro and in vivo. We further confirmed that miR-382-5p/YBX1 modulated the Ras/MAPK signaling axis to regulate the progression of LSCC.

Conclusion: Together, our results indicated that YBX1 is an important promoter of LSCC progression. And miR-382-5p/YBX1/RAS/MAPK signaling pathway can be perceived as a promising target in the treatment of LSCC.

« Previous Next »
[1]
Yanes M, Santoni G, Maret-Ouda J, et al. Laryngeal and pharyngeal squamous cell carcinoma after antireflux surgery in the 5 nordic countries. Ann Surg 2022; 276(2): e79-85.
[http://dx.doi.org/10.1097/SLA.0000000000004423] [PMID: 33074906]
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7-30.
[http://dx.doi.org/10.3322/caac.21332] [PMID: 26742998]
[3]
Wang J, Wu Y, Gao W, et al. Identification and characterization of CD133+ CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer 2017; 8(3): 497-506.
[http://dx.doi.org/10.7150/jca.17444] [PMID: 28261352]
[4]
Kosnopfel C, Sinnberg T, Schittek B. Y-box binding protein 1 - A prognostic marker and target in tumour therapy. Eur J Cell Biol 2014; 93(1-2): 61-70.
[http://dx.doi.org/10.1016/j.ejcb.2013.11.007] [PMID: 24461929]
[5]
Cui Y, Li F, Xie Q, et al. YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC. Cell Death Dis 2020; 11(6): 476.
[http://dx.doi.org/10.1038/s41419-020-2555-4]
[6]
Murugesan SN, Yadav BS, Maurya PK, Chaudhary A, Singh S, Mani A. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas. J Biosci 2019; 44(2): 27.
[http://dx.doi.org/10.1007/s12038-019-9848-8] [PMID: 31180040]
[7]
Lim JP, Shyamasundar S, Gunaratne J, Scully OJ, Matsumoto K, Bay BH. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro. BMC Cancer 2017; 17(1): 201.
[http://dx.doi.org/10.1186/s12885-017-3187-7] [PMID: 28302118]
[8]
Kosnopfel C, Sinnberg T, Sauer B, et al. YB-1 expression and phosphorylation regulate tumorigenicity and invasiveness in melanoma by influencing EMT. Mol Cancer Res 2018; 16(7): 1149-60.
[http://dx.doi.org/10.1158/1541-7786.MCR-17-0528] [PMID: 29743296]
[9]
Zhao X, Zhang W, Ji W. YB-1 promotes laryngeal squamous cell carcinoma progression by inducing miR-155 expression via c-Myb. Future Oncol 2018; 14(16): 1579-89.
[http://dx.doi.org/10.2217/fon-2018-0058] [PMID: 29517281]
[10]
Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of microRNA expression in cancer. Int J Mol Sci 2020; 21(5): 1723.
[http://dx.doi.org/10.3390/ijms21051723] [PMID: 32138313]
[11]
Kelly TJ, Brümmer A, Hooshdaran N, Tariveranmoshabad M, Zamudio JR. Temporal control of the TGF-β signaling network by mouse esc microrna targets of different affinities. Cell Rep 2019; 29(9): 2702-17.e7.
[http://dx.doi.org/10.1016/j.celrep.2019.10.109] [PMID: 31775039]
[12]
Lin XJ, Liu H, Li P, et al. MiR-936 suppresses cell proliferation, invasion, and drug resistance of laryngeal squamous cell carcinoma and targets GPR78. Front Oncol 2020; 10: 60.
[http://dx.doi.org/10.3389/fonc.2020.00060] [PMID: 32117723]
[13]
Heng-phon Z. Lihan, Zou, Ruiyang, Yeoh, et al MicroRNA biomarker for the diagnosis and treatment of gastric cancer Agency for Science, Technology and Research. United States: National University of Singapore 2020; p. 10767230.
[14]
Sun D, Li YC, Zhang XY. Lidocaine promoted ferroptosis by targeting miR-382-5p/SLC7A11 axis in ovarian and breast cancer. Front Pharmacol 2021; 12: 681223.
[http://dx.doi.org/10.3389/fphar.2021.681223] [PMID: 34122108]
[15]
Tan H, He Q, Gong G, et al. MiR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol 2016; 48(1): 181-90.
[http://dx.doi.org/10.3892/ijo.2015.3241] [PMID: 26575700]
[16]
Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: From microRNA sequences to function. Nucleic Acids Res 2019; 47(D1): D155-62.
[http://dx.doi.org/10.1093/nar/gky1141] [PMID: 30423142]
[17]
Li JH, Liu S, Zhou H, Qu LH, Yang JH. StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 2014; 42(D1): D92-7.
[http://dx.doi.org/10.1093/nar/gkt1248] [PMID: 24297251]
[18]
Sticht C, De La Torre C, Parveen A, Gretz N. MiRWalk: An online resource for prediction of microRNA binding sites. PLoS One 2018; 13(10): e0206239.
[http://dx.doi.org/10.1371/journal.pone.0206239] [PMID: 30335862]
[19]
Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife 2015; 4: e05005.
[http://dx.doi.org/10.7554/eLife.05005] [PMID: 26267216]
[20]
Huang L. Small-interfering RNA expression systems for production of small-interfering RNAs and their use. United States: City University of Hong Kong 2021; p. 11193124.
[21]
Schäfer R, Sers C. RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function. Adv Enzyme Regul 2011; 51(1): 126-36.
[http://dx.doi.org/10.1016/j.advenzreg.2010.11.005] [PMID: 21094659]
[22]
Lyabin DN, Eliseeva IA, Ovchinnikov LP. YB-1 protein: Functions and regulation. Wiley Interdiscip Rev RNA 2014; 5(1): 95-110.
[http://dx.doi.org/10.1002/wrna.1200] [PMID: 24217978]
[23]
Kuwano M, Shibata T, Watari K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci 2019; 110(5): 1536-43.
[http://dx.doi.org/10.1111/cas.14006] [PMID: 30903644]
[24]
Cybula M, Wieteska Ƚ, Józefowicz-Korczyńska M, Karbownik MS, Grzelczyk WL, Szemraj J. New miRNA expression abnormalities in laryngeal squamous cell carcinoma. Cancer Biomark 2016; 16(4): 559-68.
[http://dx.doi.org/10.3233/CBM-160598] [PMID: 27002759]
[25]
Liu D, Zhong L, Yuan Z, et al. MiR-382-5p modulates the ATRA-induced differentiation of acute promyelocytic leukemia by targeting tumor suppressor PTEN. Cell Signal 2019; 54: 1-9.
[http://dx.doi.org/10.1016/j.cellsig.2018.11.012] [PMID: 30453015]
[26]
Du J, Bai F, Zhao P, et al. Hepatitis B core protein promotes liver cancer metastasis through miR-382-5p/DLC-1 axis. Biochim Biophys Acta Mol Cell Res 2018; 1865(1): 1-11.
[http://dx.doi.org/10.1016/j.bbamcr.2017.09.020] [PMID: 28982593]
[27]
Ho JY, Hsu RJ, Liu JM, et al. MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. Oncotarget 2017; 8(14): 22443-59.
[http://dx.doi.org/10.18632/oncotarget.12338] [PMID: 27705918]
[28]
Kloetgen A, Duggimpudi S, Schuschel K. YBX1 indirectly targets heterochromatin-repressed inflammatory response-related apoptosis genes through regulating CBX5 mRNA. Int J Mol Sci 2020; 21(12): 4453.
[http://dx.doi.org/10.3390/ijms21124453] [PMID: 32585856]
[29]
Liu Z, Li Y, Li X, et al. Overexpression of ybx1 promotes pancreatic ductal adenocarcinoma growth via the gsk3b/cyclin d1/cyclin e1 pathway. Mol Ther Oncolytics 2020; 17: 21-30.
[http://dx.doi.org/10.1016/j.omto.2020.03.006] [PMID: 32300640]
[30]
Wang Y, Jing S, Wang Y, et al. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1-NF-κB signaling axis. J Exp Clin Cancer Res 2019; 38(1): 386.
[http://dx.doi.org/10.1186/s13046-019-1347-0] [PMID: 31481087]
[31]
Imada K, Shiota M, Kohashi K, et al. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res 2013; 19(17): 4638-50.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-3705] [PMID: 23838318]
[32]
Liu M, Wang X, Li H, et al. The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo. Thorac Cancer 2019; 10(10): 1868-78.
[http://dx.doi.org/10.1111/1759-7714.13162] [PMID: 31486270]
[33]
Hu H, Liu Y, Tan S, et al. Anlotinib exerts anti-cancer effects on kras-mutated lung cancer cell through suppressing the mek/erk pathway. Cancer Manag Res 2020; 12: 3579-87.
[http://dx.doi.org/10.2147/CMAR.S243660] [PMID: 32547195]
[34]
Hua Y, Wang G, Cai Z, et al. Application of novel tyrosine kinase inhibitor, anlotinib, in osteosarcoma and chondrosarcoma. Patent US2020316053A1, 2020.
[35]
Mcginn AN, Kim B. Kim , Sung C, Park CH , Cheol H. Ination therapy with apatinib for the treatment of cancer. Patent US2020282052A1, 2022.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy